Alpha-synuclein, lipids and Parkinson's disease

Progress in Lipid Research

Volumn 49, Issue 4, 2010, Pages 420-428

  Ruipérez, Violeta ^a   Darios, Frédéric ^a,b   Davletov, Bazbek ^a  

^a MRC LABORATORY OF MOLECULAR BIOLOGY   (United Kingdom)

^b SORBONNE UNIVERSITÉ   (France)

Author keywords

Alpha synuclein; Arachidonic acid; Docosahexaenoic acid; Lipid peroxidation; Lipids; Mitochondria; Oxidative stress; Parkinson's disease; Polyunsaturated fatty acids

Indexed keywords

1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; ALPHA SYNUCLEIN; ANNONACIN; ARACHIDONIC ACID; DJ 1 PROTEIN; DOCOSAHEXAENOIC ACID; FATTY ACID; LEUCINE RICH REPEAT KINASE 2; LIPID; MITOCHONDRIAL DNA; OMEGA 3 FATTY ACID; OMEGA 6 FATTY ACID; OXIDOPAMINE; PARAQUAT; PARKIN; PHOSPHOLIPID; POLYUNSATURATED FATTY ACID; REACTIVE OXYGEN METABOLITE; ROTENONE;

DISEASE ASSOCIATION; DISORDERS OF MITOCHONDRIAL FUNCTIONS; DOPAMINERGIC NERVE CELL; FATTY ACID METABOLISM; FATTY ACID OXIDATION; GENE MUTATION; HUMAN; LEWY BODY; LIPID MEMBRANE; LIPID METABOLISM; LIPID PEROXIDATION; MOTOR DYSFUNCTION; NERVE CELL DEGENERATION; NEUROPATHOLOGY; NONHUMAN; OXIDATIVE STRESS; PARKINSON DISEASE; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTEIN AGGREGATION; PROTEIN FUNCTION; PROTEIN INTERACTION; REVIEW; SUBSTANTIA NIGRA; SYMPTOM; TREMOR;

ALPHA-SYNUCLEIN; DOPAMINE; HUMANS; LEWY BODIES; LIPID METABOLISM; LIPID PEROXIDATION; MITOCHONDRIA; NEURONS; OXIDATION-REDUCTION; OXIDATIVE STRESS; PARKINSON DISEASE;

EID: 77956393934     PISSN: 01637827     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.plipres.2010.05.004     Document Type: Review

References (139)

1. A.J. Lees, J. Hardy, and T. Revesz Parkinson's disease Lancet 373 2009 2055 2066
2. A. Recchia, P. Debetto, A. Negro, D. Guidolin, S.D. Skaper, and P. Giusti Alpha-synuclein and Parkinson's disease FASEB J 18 2004 617 626
3. J.W. Langston, P. Ballard, J.W. Tetrud, and I. Irwin Chronic Parkinsonism in humans due to a product of meperidine-analog synthesis Science 219 1983 979 980
4. E.C. Hirsch, G. Hoglinger, E. Rousselet, T. Breidert, K. Parain, and J. Feger Animal models of Parkinson's disease in rodents induced by toxins: an update J Neural Transm Suppl 2003 89 100
5. J. Lotharius, L.L. Dugan, and K.L. O'Malley Distinct mechanisms underlie neurotoxin-mediated cell death in cultured dopaminergic neurons J Neurosci 19 1999 1284 1293
6. Y.Y. Glinka, and M.B. Youdim Inhibition of mitochondrial complexes I and IV by 6-hydroxydopamine Eur J Pharmacol 292 1995 329 332
7. M.G. Spillantini, M.L. Schmidt, V.M. Lee, J.Q. Trojanowski, R. Jakes, and M. Goedert Alpha-synuclein in Lewy bodies Nature 388 1997 839 840
8. M.H. Polymeropoulos, C. Lavedan, E. Leroy, S.E. Ide, A. Dehejia, and A. Dutra Mutation in the alpha-synuclein gene identified in families with Parkinson's disease Science 276 1997 2045 2047
9. R. Kruger, W. Kuhn, T. Muller, D. Woitalla, M. Graeber, and S. Kosel Ala30Pro mutation in the gene encoding alpha-synuclein in Parkinson's disease Nat Genet 18 1998 106 108
10. J.J. Zarranz, J. Alegre, J.C. Gomez-Esteban, E. Lezcano, R. Ros, and I. Ampuero The new mutation, E46K, of alpha-synuclein causes Parkinson and Lewy body dementia Ann Neurol 55 2004 164 173
11. A.B. Singleton, M. Farrer, J. Johnson, A. Singleton, S. Hague, and J. Kachergus Alpha-synuclein locus triplication causes Parkinson's disease Science 302 2003 841
12. P. Ibanez, A.M. Bonnet, B. Debarges, E. Lohmann, F. Tison, and P. Pollak Causal relation between alpha-synuclein gene duplication and familial Parkinson's disease Lancet 364 2004 1169 1171
13. M.C. Chartier-Harlin, J. Kachergus, C. Roumier, V. Mouroux, X. Douay, and S. Lincoln Alpha-synuclein locus duplication as a cause of familial Parkinson's disease Lancet 364 2004 1167 1169
14. K. Nishioka, S. Hayashi, M.J. Farrer, A.B. Singleton, H. Yoshino, and H. Imai Clinical heterogeneity of alpha-synuclein gene duplication in Parkinson's disease Ann Neurol 59 2006 298 309
15. R. Kruger, T. Muller, and O. Riess Involvement of alpha-synuclein in Parkinson's disease and other neurodegenerative disorders J Neural Transm 107 2000 31 40
16. W.S. Davidson, A. Jonas, D.F. Clayton, and J.M. George Stabilization of alpha-synuclein secondary structure upon binding to synthetic membranes J Biol Chem 273 1998 9443 9449
17. E. Jo, J. McLaurin, C.M. Yip, P. St. George-Hyslop, and P.E. Fraser Alpha-synuclein membrane interactions and lipid specificity J Biol Chem 275 2000 34328 34334
18. M. Stockl, P. Fischer, E. Wanker, and A. Herrmann Alpha-synuclein selectively binds to anionic phospholipids embedded in liquid-disordered domains J Mol Biol 375 2008 1394 1404
19. C.R. Bodner, A.S. Maltsev, C.M. Dobson, and A. Bax Differential phospholipid binding of alpha-synuclein variants implicated in Parkinson's disease revealed by solution NMR spectroscopy Biochemistry 49 2010 862 871
20. R. Sharon, M.S. Goldberg, I. Bar-Josef, R.A. Betensky, J. Shen, and D.J. Selkoe Alpha-synuclein occurs in lipid-rich high molecular weight complexes, binds fatty acids, and shows homology to the fatty acid-binding proteins Proc Natl Acad Sci USA 98 2001 9110 9115
21. C. Lucke, D.L. Gantz, E. Klimtchuk, and J.A. Hamilton Interactions between fatty acids and alpha-synuclein J Lipid Res 47 2006 1714 1724
22. S.A. Salem, D. Allsop, D.M. Mann, T. Tokuda, and O.M. El-Agnaf An investigation into the lipid-binding properties of alpha-, beta- and gamma-synucleins in human brain and cerebrospinal fluid Brain Res 1170 2007 103 111
23. N.B. Cole, D.D. Murphy, T. Grider, S. Rueter, D. Brasaemle, and R.L. Nussbaum Lipid droplet binding and oligomerization properties of the Parkinson's disease protein alpha-synuclein J Biol Chem 277 2002 6344 6352
24. R.L. Miller, M. James-Kracke, G.Y. Sun, and A.Y. Sun Oxidative and inflammatory pathways in Parkinson's disease Neurochem Res 34 2009 55 65
25. B. Su, X. Wang, L. Zheng, G. Perry, M.A. Smith, and X. Zhu Abnormal mitochondrial dynamics and neurodegenerative diseases Biochim Biophys Acta 1802 2010 135 142
26. C.T. Chen, J.T. Green, S.K. Orr, and R.P. Bazinet Regulation of brain polyunsaturated fatty acid uptake and turnover Prostaglandins Leukot Essent Fatty Acids 79 2008 85 91
27. J.A. Hamilton, and K. Brunaldi A model for fatty acid transport into the brain J Mol Neurosci 33 2007 12 17
28. B.H. Anderton Changes in the ageing brain in health and disease Philos Trans R Soc Lond B Biol Sci 352 1997 1781 1792
29. L. Svennerholm Distribution and fatty acid composition of phosphoglycerides in normal human brain J Lipid Res 9 1968 570 579
30. F. Darios, and B. Davletov Omega-3 and omega-6 fatty acids stimulate cell membrane expansion by acting on syntaxin 3 Nature 440 2006 813 817
31. E. Connell, F. Darios, K. Broersen, N. Gatsby, S.Y. Peak-Chew, and C. Rickman Mechanism of arachidonic acid action on syntaxin-Munc18 EMBO Rep 8 2007 414 419
32. F. Darios, E. Connell, and B. Davletov Phospholipases and fatty acid signalling in exocytosis J Physiol 585 2007 699 704
33. J. Balsinde, R. Perez, and M.A. Balboa Calcium-independent phospholipase A2 and apoptosis Biochim Biophys Acta 1761 2006 1344 1350
34. S.P. Herbert, and J.H. Walker Group VIA calcium-independent phospholipase A2 mediates endothelial cell S phase progression J Biol Chem 281 2006 35709 35716
35. R.E. Wooten, M.C. Willingham, L.W. Daniel, C.C. Leslie, L.C. Rogers, and S. Sergeant Novel translocation responses of cytosolic phospholipase A2alpha fluorescent proteins Biochim Biophys Acta 1783 2008 1544 1550
36. N. Flamand, J. Lefebvre, M.E. Surette, S. Picard, and P. Borgeat Arachidonic acid regulates the translocation of 5-lipoxygenase to the nuclear membranes in human neutrophils J Biol Chem 281 2006 129 136
37. G. Schmitz, and J. Ecker The opposing effects of n-3 and n-6 fatty acids Prog Lipid Res 47 2008 147 155
38. S. Florent-Bechard, C. Desbene, P. Garcia, A. Allouche, I. Youssef, and M.C. Escanye The essential role of lipids in Alzheimer's disease Biochimie 91 2009 804 809
39. R.M. Lane, and M.R. Farlow Lipid homeostasis and apolipoprotein E in the development and progression of Alzheimer's disease J Lipid Res 46 2005 949 968
40. F. Bosetti Arachidonic acid metabolism in brain physiology and pathology: lessons from genetically altered mouse models J Neurochem 102 2007 577 586
41. J. Bras, A. Singleton, M.R. Cookson, and J. Hardy Emerging pathways in genetic Parkinson's disease: potential role of ceramide metabolism in Lewy body disease FEBS J 275 2008 5767 5773
42. A.A. Farooqui, W.Y. Ong, and L.A. Horrocks Inhibitors of brain phospholipase A2 activity: their neuropharmacological effects and therapeutic importance for the treatment of neurologic disorders Pharmacol Rev 58 2006 591 620
43. A.A. Farooqui, and L.A. Horrocks Phospholipase A2-generated lipid mediators in the brain: the good, the bad, and the ugly Neuroscientist 12 2006 245 260
44. A.A. Farooqui, H.C. Yang, T.A. Rosenberger, and L.A. Horrocks Phospholipase A2 and its role in brain tissue J Neurochem 69 1997 889 901
45. C. Knott, G. Stern, and G.P. Wilkin Inflammatory regulators in Parkinson's disease: iNOS, lipocortin-1, and cyclooxygenases-1 and -2 Mol Cell Neurosci 16 2000 724 739
46. N.V. Morgan, S.K. Westaway, J.E. Morton, A. Gregory, P. Gissen, and S. Sonek PLA2G6, encoding a phospholipase A2, is mutated in neurodegenerative disorders with high brain iron Nat Genet 38 2006 752 754
47. S. Akiba, and T. Sato Cellular function of calcium-independent phospholipase A2 Biol Pharm Bull 27 2004 1174 1178
48. A. Gregory, S.K. Westaway, I.E. Holm, P.T. Kotzbauer, P. Hogarth, and S. Sonek Neurodegeneration associated with genetic defects in phospholipase A(2) Neurology 71 2008 1402 1409
49. M. Tariq, H.A. Khan, K. Al Moutaery, and S. Al Deeb Protective effect of quinacrine on striatal dopamine levels in 6-OHDA and MPTP models of Parkinsonism in rodents Brain Res Bull 54 2001 77 82
50. N. Uozumi, K. Kume, T. Nagase, N. Nakatani, S. Ishii, and F. Tashiro Role of cytosolic phospholipase A2 in allergic response and parturition Nature 390 1997 618 622
51. J.V. Bonventre, Z. Huang, M.R. Taheri, E. O'Leary, E. Li, and M.A. Moskowitz Reduced fertility and postischaemic brain injury in mice deficient in cytosolic phospholipase A2 Nature 390 1997 622 625
52. T.A. Rosenberger, N.E. Villacreses, M.A. Contreras, J.V. Bonventre, and S.I. Rapoport Brain lipid metabolism in the cPLA2 knockout mouse J Lipid Res 44 2003 109 117
53. P. Klivenyi, M.F. Beal, R.J. Ferrante, O.A. Andreassen, M. Wermer, and M.R. Chin Mice deficient in group IV cytosolic phospholipase A2 are resistant to MPTP neurotoxicity J Neurochem 71 1998 2634 2637
54. George JM. The synucleins. Genome Biol 2002;3:REVIEWS3002.
55. K. Welch, and J. Yuan Alpha-synuclein oligomerization: a role for lipids? Trends Neurosci 26 2003 517 519
56. R.J. Perrin, W.S. Woods, D.F. Clayton, and J.M. George Exposure to long chain polyunsaturated fatty acids triggers rapid multimerization of synucleins J Biol Chem 276 2001 41958 41962
57. R. Sharon, I. Bar-Joseph, M.P. Frosch, D.M. Walsh, J.A. Hamilton, and D.J. Selkoe The formation of highly soluble oligomers of alpha-synuclein is regulated by fatty acids and enhanced in Parkinson's disease Neuron 37 2003 583 595
58. K. Assayag, E. Yakunin, V. Loeb, D.J. Selkoe, and R. Sharon Polyunsaturated fatty acids induce alpha-synuclein-related pathogenic changes in neuronal cells Am J Pathol 171 2007 2000 2011
59. K. Broersen, D. van den Brink, G. Fraser, M. Goedert, and B. Davletov Alpha-synuclein adopts an alpha-helical conformation in the presence of polyunsaturated fatty acids to hinder micelle formation Biochemistry 45 2006 15610 15616
60. W.J. Lukiw, and N.G. Bazan Docosahexaenoic acid and the aging brain J Nutr 138 2008 2510 2514
61. R. Sharon, I. Bar-Joseph, G.E. Mirick, C.N. Serhan, and D.J. Selkoe Altered fatty acid composition of dopaminergic neurons expressing alpha-synuclein and human brains with alpha-synucleinopathies J Biol Chem 278 2003 49874 49881
62. G. De Franceschi, E. Frare, L. Bubacco, S. Mammi, A. Fontana, and P.P. de Laureto Molecular insights into the interaction between alpha-synuclein and docosahexaenoic acid J Mol Biol 394 2009 94 107
63. H. Karube, M. Sakamoto, S. Arawaka, S. Hara, H. Sato, and C.H. Ren N-terminal region of alpha-synuclein is essential for the fatty acid-induced oligomerization of the molecules FEBS Lett 582 2008 3693 3700
64. M.Y. Golovko, T.A. Rosenberger, S. Feddersen, N.J. Faergeman, and E.J. Murphy Alpha-synuclein gene ablation increases docosahexaenoic acid incorporation and turnover in brain phospholipids J Neurochem 101 2007 201 211
65. M.Y. Golovko, T.A. Rosenberger, N.J. Faergeman, S. Feddersen, N.B. Cole, and I. Pribill Acyl-CoA synthetase activity links wild-type but not mutant alpha-synuclein to brain arachidonate metabolism Biochemistry 45 2006 6956 6966
66. M.Y. Golovko, G. Barcelo-Coblijn, P.I. Castagnet, S. Austin, C.K. Combs, and E.J. Murphy The role of alpha-synuclein in brain lipid metabolism: a downstream impact on brain inflammatory response Mol Cell Biochem 326 2009 55 66
67. G. Barcelo-Coblijn, M.Y. Golovko, I. Weinhofer, J. Berger, and E.J. Murphy Brain neutral lipids mass is increased in alpha-synuclein gene-ablated mice J Neurochem 101 2007 132 141
68. P.I. Castagnet, M.Y. Golovko, G.C. Barcelo-Coblijn, R.L. Nussbaum, and E.J. Murphy Fatty acid incorporation is decreased in astrocytes cultured from alpha-synuclein gene-ablated mice J Neurochem 94 2005 839 849
69. A.A. Farooqui, and L.A. Horrocks Lipid peroxides in the free radical pathophysiology of brain diseases Cell Mol Neurobiol 18 1998 599 608
70. D. Dexter, C. Carter, F. Agid, Y. Agid, A.J. Lees, and P. Jenner Lipid peroxidation as cause of nigral cell death in Parkinson's disease Lancet 2 1986 639 640
71. P. Teismann, M. Vila, D.K. Choi, K. Tieu, D.C. Wu, and V. Jackson-Lewis COX-2 and neurodegeneration in Parkinson's disease Ann NY Acad Sci 991 2003 272 277
72. E.E. Tuppo, and H.R. Arias The role of inflammation in Alzheimer's disease Int J Biochem Cell Biol 37 2005 289 305
73. N.G. Bazan, V. Colangelo, and W.J. Lukiw Prostaglandins and other lipid mediators in Alzheimer's disease Prostaglandins Other Lipid Mediat 68-69 2002 197 210
74. W.L. Smith, and R. Langenbach Why there are two cyclooxygenase isozymes J Clin Invest 107 2001 1491 1495
75. T. Wyss-Coray, and L. Mucke Ibuprofen, inflammation and Alzheimer disease Nat Med 6 2000 973 974
76. P. Teismann, and B. Ferger Inhibition of the cyclooxygenase isoenzymes COX-1 and COX-2 provide neuroprotection in the MPTP-mouse model of Parkinson's disease Synapse 39 2001 167 174
77. Z. Feng, D. Li, P.C. Fung, Z. Pei, D.B. Ramsden, and S.L. Ho COX-2-deficient mice are less prone to MPTP-neurotoxicity than wild-type mice Neuroreport 14 2003 1927 1929
78. Z.H. Feng, T.G. Wang, D.D. Li, P. Fung, B.C. Wilson, and B. Liu Cyclooxygenase-2-deficient mice are resistant to 1-methyl-4-phenyl 1, 2, 3, 6-tetrahydropyridine-induced damage of dopaminergic neurons in the substantia nigra Neurosci Lett 329 2002 354 358
79. S. Aid, R. Langenbach, and F. Bosetti Neuroinflammatory response to lipopolysaccharide is exacerbated in mice genetically deficient in cyclooxygenase-2 J Neuroinflammation 5 2008 17
80. E. Kikawada, J.V. Bonventre, and J.P. Arm Group V secretory PLA2 regulates TLR2-dependent eicosanoid generation in mouse mast cells through amplification of ERK and cPLA2alpha activation Blood 110 2007 561 567
81. H. Shinohara, M.A. Balboa, C.A. Johnson, J. Balsinde, and E.A. Dennis Regulation of delayed prostaglandin production in activated P388D1 macrophages by group IV cytosolic and group V secretory phospholipase A2s J Biol Chem 274 1999 12263 12268
82. J. Balsinde, H. Shinohara, L.J. Lefkowitz, C.A. Johnson, M.A. Balboa, and E.A. Dennis Group V phospholipase A(2)-dependent induction of cyclooxygenase-2 in macrophages J Biol Chem 274 1999 25967 25970
83. H. Fujishima, R.O. Sanchez Mejia, C.O. Bingham 3rd, B.K. Lam, A. Sapirstein, and J.V. Bonventre Cytosolic phospholipase A2 is essential for both the immediate and the delayed phases of eicosanoid generation in mouse bone marrow-derived mast cells Proc Natl Acad Sci USA 96 1999 4803 4807
84. T.G. Hastings Enzymatic oxidation of dopamine: the role of prostaglandin H synthase J Neurochem 64 1995 919 924
85. Y.Y. Tyurina, A.A. Kapralov, J. Jiang, G.G. Borisenko, A.I. Potapovich, and A. Sorokin Oxidation and cytotoxicity of 6-OHDA are mediated by reactive intermediates of COX-2 overexpressed in PC12 cells Brain Res 1093 2006 71 82
86. T. Wang, Z. Pei, W. Zhang, B. Liu, R. Langenbach, and C. Lee MPP+ -induced COX-2 activation and subsequent dopaminergic neurodegeneration FASEB J 19 2005 1134 1136
87. M.C. Quilty, A.E. King, W.P. Gai, D.L. Pountney, A.K. West, and J.C. Vickers Alpha-synuclein is upregulated in neurones in response to chronic oxidative stress and is associated with neuroprotection Exp Neurol 199 2006 249 256
88. M. Hashimoto, L.J. Hsu, E. Rockenstein, T. Takenouchi, M. Mallory, and E. Masliah Alpha-synuclein protects against oxidative stress via inactivation of the c-Jun N-terminal kinase stress-signaling pathway in neuronal cells J Biol Chem 277 2002 11465 11472
89. M. Zhu, Z.J. Qin, D. Hu, L.A. Munishkina, and A.L. Fink Alpha-synuclein can function as an antioxidant preventing oxidation of unsaturated lipid in vesicles Biochemistry 45 2006 8135 8142
90. R.G. Perez, J.C. Waymire, E. Lin, J.J. Liu, F. Guo, and M.J. Zigmond A role for alpha-synuclein in the regulation of dopamine biosynthesis J Neurosci 22 2002 3090 3099
91. C. Wersinger, P. Vernier, and A. Sidhu Trypsin disrupts the trafficking of the human dopamine transporter by alpha-synuclein and its A30P mutant Biochemistry 43 2004 1242 1253
92. F.J. Lee, F. Liu, Z.B. Pristupa, and H.B. Niznik Direct binding and functional coupling of alpha-synuclein to the dopamine transporters accelerate dopamine-induced apoptosis FASEB J 15 2001 916 926
93. W.M. Caudle, J.R. Richardson, M.Z. Wang, T.N. Taylor, T.S. Guillot, and A.L. McCormack Reduced vesicular storage of dopamine causes progressive nigrostriatal neurodegeneration J Neurosci 27 2007 8138 8148
94. R.E. Colebrooke, T. Humby, P.J. Lynch, D.P. McGowan, J. Xia, and P.C. Emson Age-related decline in striatal dopamine content and motor performance occurs in the absence of nigral cell loss in a genetic mouse model of Parkinson's disease Eur J Neurosci 24 2006 2622 2630
95. J. Lotharius, and P. Brundin Pathogenesis of Parkinson's disease: dopamine, vesicles and alpha-synuclein Nat Rev Neurosci 3 2002 932 942
96. D.G. Graham Oxidative pathways for catecholamines in the genesis of neuromelanin and cytotoxic quinones Mol Pharmacol 14 1978 633 643
97. H.S. Maker, C. Weiss, D.J. Silides, and G. Cohen Coupling of dopamine oxidation (monoamine oxidase activity) to glutathione oxidation via the generation of hydrogen peroxide in rat brain homogenates J Neurochem 36 1981 589 593
98. F. Zoccarato, P. Toscano, and A. Alexandre Dopamine-derived dopaminochrome promotes H(2)O(2) release at mitochondrial complex I: stimulation by rotenone, control by Ca(2+), and relevance to Parkinson disease J Biol Chem 280 2005 15587 15594
99. T. Xia, P. Korge, J.N. Weiss, N. Li, M.I. Venkatesen, and C. Sioutas Quinones and aromatic chemical compounds in particulate matter induce mitochondrial dysfunction: implications for ultrafine particle toxicity Environ Health Perspect 112 2004 1347 1358
100. M. Asanuma, I. Miyazaki, and N. Ogawa Dopamine- or L-DOPA-induced neurotoxicity: the role of dopamine quinone formation and tyrosinase in a model of Parkinson's disease Neurotox Res 5 2003 165 176
101. W. Zhou, A. Gallagher, D.P. Hong, C. Long, A.L. Fink, and V.N. Uversky At low concentrations, 3, 4-dihydroxyphenylacetic acid (DOPAC) binds non-covalently to alpha-synuclein and prevents its fibrillation J Mol Biol 388 2009 597 610
102. S. Krishnan, E.Y. Chi, S.J. Wood, B.S. Kendrick, C. Li, and W. Garzon-Rodriguez Oxidative dimer formation is the critical rate-limiting step for Parkinson's disease alpha-synuclein fibrillogenesis Biochemistry 42 2003 829 837
103. S.L. Leong, R. Cappai, K.J. Barnham, and L. Pham Cle Modulation of alpha-synuclein aggregation by dopamine: a review Neurochem Res 34 2009 1838 1846
104. X. Liu, N. Yamada, W. Maruyama, and T. Osawa Formation of dopamine adducts derived from brain polyunsaturated fatty acids: mechanism for Parkinson disease J Biol Chem 283 2008 34887 34895
105. A. Bender, K.J. Krishnan, C.M. Morris, G.A. Taylor, A.K. Reeve, and R.H. Perry High levels of mitochondrial DNA deletions in substantia nigra neurons in aging and Parkinson disease Nat Genet 38 2006 515 517
106. Y. Kraytsberg, E. Kudryavtseva, A.C. McKee, C. Geula, N.W. Kowall, and K. Khrapko Mitochondrial DNA deletions are abundant and cause functional impairment in aged human substantia nigra neurons Nat Genet 38 2006 518 520
107. R. Smigrodzki, J. Parks, and W.D. Parker High frequency of mitochondrial complex I mutations in Parkinson's disease and aging Neurobiol Aging 25 2004 1273 1281
108. J.M. Savitt, V.L. Dawson, and T.M. Dawson Diagnosis and treatment of Parkinson disease: molecules to medicine J Clin Invest 116 2006 1744 1754
109. W. Mandemakers, V.A. Morais, and B. De Strooper A cell biological perspective on mitochondrial dysfunction in Parkinson disease and other neurodegenerative diseases J Cell Sci 120 2007 1707 1716
110. R. Betarbet, T.B. Sherer, and J.T. Greenamyre Animal models of Parkinson's disease Bioessays 24 2002 308 318
111. U. Ungerstedt 6-Hydroxy-dopamine induced degeneration of central monoamine neurons Eur J Pharmacol 5 1968 107 110
112. G.U. Hoglinger, G. Carrard, P.P. Michel, F. Medja, A. Lombes, and M. Ruberg Dysfunction of mitochondrial complex I and the proteasome: interactions between two biochemical deficits in a cellular model of Parkinson's disease J Neurochem 86 2003 1297 1307
113. P. Champy, G.U. Hoglinger, J. Feger, C. Gleye, R. Hocquemiller, and A. Laurens Annonacin, a lipophilic inhibitor of mitochondrial complex I, induces nigral and striatal neurodegeneration in rats: possible relevance for atypical parkinsonism in Guadeloupe J Neurochem 88 2004 63 69
114. R.H. Swerdlow, J.K. Parks, J.N. Davis 2nd, D.S. Cassarino, P.A. Trimmer, and L.J. Currie Matrilineal inheritance of complex I dysfunction in a multigenerational Parkinson's disease family Ann Neurol 44 1998 873 881
115. F. Darios, O. Corti, C.B. Lucking, C. Hampe, M.P. Muriel, and N. Abbas Parkin prevents mitochondrial swelling and cytochrome c release in mitochondria-dependent cell death Hum Mol Genet 12 2003 517 526
116. I.F. Mata, W.J. Wedemeyer, M.J. Farrer, J.P. Taylor, and K.A. Gallo LRRK2 in Parkinson's disease: protein domains and functional insights Trends Neurosci 29 2006 286 293
117. E.M. Valente, S. Salvi, T. Ialongo, R. Marongiu, A.E. Elia, and V. Caputo PINK1 mutations are associated with sporadic early-onset parkinsonism Ann Neurol 56 2004 336 341
118. R.M. Canet-Aviles, M.A. Wilson, D.W. Miller, R. Ahmad, C. McLendon, and S. Bandyopadhyay The Parkinson's disease protein DJ-1 is neuroprotective due to cysteine-sulfinic acid-driven mitochondrial localization Proc Natl Acad Sci USA 101 2004 9103 9108
119. D.J. Keating Mitochondrial dysfunction, oxidative stress, regulation of exocytosis and their relevance to neurodegenerative diseases J Neurochem 104 2008 298 305
120. A.R. Giniatullin, F. Darios, A. Shakirzyanova, B. Davletov, and R. Giniatullin SNAP25 is a pre-synaptic target for the depressant action of reactive oxygen species on transmitter release J Neurochem 98 2006 1789 1797
121. D.T. Chang, and I.J. Reynolds Mitochondrial trafficking and morphology in healthy and injured neurons Prog Neurobiol 80 2006 241 268
122. C.L. Liang, T.T. Wang, K. Luby-Phelps, and D.C. German Mitochondria mass is low in mouse substantia nigra dopamine neurons: implications for Parkinson's disease Exp Neurol 203 2007 370 380
123. K. Nakamura, V.M. Nemani, E.K. Wallender, K. Kaehlcke, M. Ott, and R.H. Edwards Optical reporters for the conformation of alpha-synuclein reveal a specific interaction with mitochondria J Neurosci 28 2008 12305 12317
124. S. Shavali, H.M. Brown-Borg, M. Ebadi, and J. Porter Mitochondrial localization of alpha-synuclein protein in alpha-synuclein overexpressing cells Neurosci Lett 439 2008 125 128
125. W.W. Li, R. Yang, J.C. Guo, H.M. Ren, X.L. Zha, and J.S. Cheng Localization of alpha-synuclein to mitochondria within midbrain of mice Neuroreport 18 2007 1543 1546
126. V. Loeb, E. Yakunin, A. Saada, and R. Sharon The transgenic overexpression of alpha-synuclein and not its related pathology associates with complex I inhibition J Biol Chem 285 2010 7334 7343
127. L. Devi, V. Raghavendran, B.M. Prabhu, N.G. Avadhani, and H.K. Anandatheerthavarada Mitochondrial import and accumulation of alpha-synuclein impair complex I in human dopaminergic neuronal cultures and Parkinson disease brain J Biol Chem 283 2008 9089 9100
128. M.S. Parihar, A. Parihar, M. Fujita, M. Hashimoto, and P. Ghafourifar Alpha-synuclein overexpression and aggregation exacerbates impairment of mitochondrial functions by augmenting oxidative stress in human neuroblastoma cells Int J Biochem Cell Biol 41 2009 2015 2024
129. M.S. Parihar, A. Parihar, M. Fujita, M. Hashimoto, and P. Ghafourifar Mitochondrial association of alpha-synuclein causes oxidative stress Cell Mol Life Sci 65 2008 1272 1284
130. A.R. Saha, N.N. Ninkina, D.P. Hanger, B.H. Anderton, A.M. Davies, and V.L. Buchman Induction of neuronal death by alpha-synuclein Eur J Neurosci 12 2000 3073 3077
131. A.B. Manning-Bog, A.L. McCormack, M.G. Purisai, L.M. Bolin, and D.A. Di Monte Alpha-synuclein overexpression protects against paraquat-induced neurodegeneration J Neurosci 23 2003 3095 3099
132. H. Bayir, A.A. Kapralov, J. Jiang, Z. Huang, Y.Y. Tyurina, and V.A. Tyurin Peroxidase mechanism of lipid-dependent cross-linking of synuclein with cytochrome C: protection against apoptosis versus delayed oxidative stress in Parkinson disease J Biol Chem 284 2009 15951 15969
133. S. Kaul, V. Anantharam, A. Kanthasamy, and A.G. Kanthasamy Wild-type alpha-synuclein interacts with pro-apoptotic proteins PKCdelta and BAD to protect dopaminergic neuronal cells against MPP+-induced apoptotic cell death Brain Res Mol Brain Res 139 2005 137 152
134. C.A. da Costa, K. Ancolio, and F. Checler Wild-type but not Parkinson's disease-related ala-53 Thr mutant alpha -synuclein protects neuronal cells from apoptotic stimuli J Biol Chem 275 2000 24065 24069
135. B. Monti, E. Polazzi, L. Batti, C. Crochemore, M. Virgili, and A. Contestabile Alpha-synuclein protects cerebellar granule neurons against 6-hydroxydopamine-induced death J Neurochem 103 2007 518 530
136. C.E. Ellis, E.J. Murphy, D.C. Mitchell, M.Y. Golovko, F. Scaglia, and G.C. Barcelo-Coblijn Mitochondrial lipid abnormality and electron transport chain impairment in mice lacking alpha-synuclein Mol Cell Biol 25 2005 10190 10201
137. P. Klivenyi, D. Siwek, G. Gardian, L. Yang, A. Starkov, and C. Cleren Mice lacking alpha-synuclein are resistant to mitochondrial toxins Neurobiol Dis 21 2006 541 548
138. W. Dauer, N. Kholodilov, M. Vila, A.C. Trillat, R. Goodchild, and K.E. Larsen Resistance of alpha -synuclein null mice to the parkinsonian neurotoxin MPTP Proc Natl Acad Sci USA 99 2002 14524 14529
139. T.M. Dawson, and V.L. Dawson Molecular pathways of neurodegeneration in Parkinson's disease Science 302 2003 819 822